Skip to content

Registry on Left Main Coronary Artery Bifurcation Percutaneous Intervention

Web-based Registry on Left Main From the Euro Bifurcation Club (WE REMAIN EBC)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04321473
Acronym
WE REMAIN EBC
Enrollment
1500
Registered
2020-03-25
Start date
2020-09-01
Completion date
2021-09-30
Last updated
2020-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Arteriosclerosis, Left Main Coronary Artery Disease

Brief summary

The slowly accruing evidence on the treatment of patients with left main coronary artery (LMCA) disease drove evolution in guidelines, that currently establish equivalent safety and efficacy for percutaneous coronary intervention (PCI) as compared to surgery, with a class of recommendation that is subjected to the extension and complexity of concomitant coronary artery disease, as assessed by the SYNTAX score. The severity of LMCA disease, although extremely relevant due to the extent of the supplied myocardium, is often difficult to assess with traditional angiography, due to lack of appropriate angiographic views, absence of a true reference segment, interaction with the intubating catheter. Intravascular techniques with either imaging or functional assessment have been variously tested, although with a disturbing rate of discordant results; moreover, they are frequently underused for a number of reasons, including the additional time needed to assess both left anterior descending (LAD) and left circumflex (LCx) arteries, technical challenges, costs and the small risk associated with maneuvering such devices. Fractional flow reserve (FFR) measured from the coronary angiogram (FFRangio) alone recently documented a high diagnostic accuracy compared with pressure-wire derived FFR. As for the anatomical localization, the majority of LMCA lesions occur at the bifurcation, where PCI results are less favourable. The distal LMCA differs from the other bifurcations in several characteristics: a) a notable mismatch between the LMCA and the left anterior descending (LAD) artery, hampering the selection of an adequately sized stent, b) the presence of a trifurcation, with a large ramus arising from LMCA in about 10% of cases, c) the presence of left or co-dominant circulation, with the LMCA supplying all or nearly all left ventricular myocardium in about 15% of cases. Therefore, although the European Bifurcation Club (EBC) recommends a provisional side branch approach in most cases of distal LMCA disease, the threshold for placing a second stent in the side branch may be lower in lesions located on LM bifurcation compared with non-LMCA bifurcations. As for double stenting, the evidence is controversial and a consensus is lacking. Moreover, the optimal treatment of patients with LM trifurcations is still undefined. The aim of this study is therefore to determine the optimal strategy for the treatment of LM bifurcated lesions.

Detailed description

PCI access site and technique will be left at the operator's discretion, as well as antithrombotic management. No limitation will be applied for the technique of PCI. As regards data collection and endpoints, Case Report Form (CRF) will be entered on a web-based platform, where study participants will be able to access and retrieve data at any time during study progress. In-hospital outcomes will be recorded; all patients discharged alive will be followed up with a 30-day, 6-month, and 1-year telephone interview. On a center-to-center voluntary basis, pre-PCI and post-PCI angiographic images (made blind regarding patients' identity) will be sent to a study angiographic core-lab for Quantitative Angiography Substudy. The images will be processed using a validated quantitative coronary angiography (QCA) Bifurcation software to assess quantitative data describing bifurcation geometry before and after LMCA PCI. In the Quantitative Angiography Substudy, on exploratory bases, FFRangio data reconstructed by angiographic software will be tested against stenosis LMCA lesion severity and LMCA PCI result.

Interventions

PROCEDUREPCI on left main

PCI on left main coronary stenosis

Sponsors

Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti
CollaboratorOTHER
Hospital Clínico Universitario de Valladolid
CollaboratorOTHER
VZW Cardiovascular Research Center Aalst
CollaboratorOTHER
Federico II University
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
CollaboratorOTHER
Clinica Mediterranea
CollaboratorOTHER
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
CollaboratorOTHER
San Raffaele University Hospital, Italy
CollaboratorOTHER
Instituto Dante Pazzanese de Cardiologia
CollaboratorOTHER
University Medical Centre Maribor
CollaboratorOTHER
Clinica Di Montevergine
CollaboratorOTHER
Clinical Hospital Centre Zagreb
CollaboratorOTHER
Clinical Centre of Serbia
CollaboratorOTHER
Chiba University
CollaboratorOTHER
Université Paris-Sud
CollaboratorOTHER
Hospital Universitario Reina Sofia de Cordoba
CollaboratorOTHER_GOV
Mount Sinai Hospital, New York
CollaboratorOTHER
Hospital Pablo Tobón Uribe
CollaboratorOTHER
Pauls Stradins Clinical University Hospital
CollaboratorOTHER
University Hospital Monastir, Tunis
CollaboratorOTHER
G. d'Annunzio University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients ≥18 years of age with a diagnosis of documented silent ischemia, stable angina, or acute coronary syndrome (ACS). * PCI with single or multiple drug-eluting stent (DES) for the treatment of lesion located at LMCA bifurcation and defined as a diameter stenosis of ≥50% by visual estimation.

Exclusion criteria

* Patients who cannot give informed consent or have a life expectancy of ≤12 months; * Pregnant or nursing mothers. Women of child-bearing age will be asked if they are pregnant or think that they may be pregnant. * Contraindication or suspected intolerance to anticoagulant (heparin, bivalirudin) or oral antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor).

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiac events (MACE)12 monthsThe composite of: death from any cause, myocardial infarction (MI), stent thrombosis (ST), defined as definite, probable or possible following the Academic Research Consortium.

Secondary

MeasureTime frameDescription
MI12 monthsMyocardial Infarction
ST12 monthsStent thrombosis (definite, probable or possible)
Death12 monthsAll-cause death and cardiovascular death
Target Vessel Revascularization (TVR)12 MonthsTarget Vessel Revascularization
Bleeding12 MonthsThe occurrence of major bleeding, as a bleeding defined by the academic research consortium (BARC)- classified as type 3 (a, b or c) or 5 bleeding event
In-hospital MACE12 MonthsComposite of death, MI and ST

Contacts

Primary ContactMarco Zimarino, MD, PhD
m.zimarino@unich.it+39 3476045261

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026